These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. NMR structure of the DNA decamer duplex containing double T*G mismatches of cis-syn cyclobutane pyrimidine dimer: implications for DNA damage recognition by the XPC-hHR23B complex. Lee JH; Park CJ; Shin JS; Ikegami T; Akutsu H; Choi BS Nucleic Acids Res; 2004; 32(8):2474-81. PubMed ID: 15121904 [TBL] [Abstract][Full Text] [Related]
27. Solution structure and stability of the DNA undecamer duplexes containing oxanine mismatch. Pack SP; Morimoto H; Makino K; Tajima K; Kanaori K Nucleic Acids Res; 2012 Feb; 40(4):1841-55. PubMed ID: 22039100 [TBL] [Abstract][Full Text] [Related]
28. Small molecule inhibitors of DNA repair nuclease activities of APE1. Wilson DM; Simeonov A Cell Mol Life Sci; 2010 Nov; 67(21):3621-31. PubMed ID: 20809131 [TBL] [Abstract][Full Text] [Related]
29. DNA mismatch repair in eukaryotes and bacteria. Fukui K J Nucleic Acids; 2010 Jul; 2010():. PubMed ID: 20725617 [TBL] [Abstract][Full Text] [Related]
30. Targeting DNA repair proteins for cancer treatment. Tell G; Wilson DM Cell Mol Life Sci; 2010 Nov; 67(21):3569-72. PubMed ID: 20706767 [No Abstract] [Full Text] [Related]
31. A review of PARP inhibitors: from bench to bedside. Underhill C; Toulmonde M; Bonnefoi H Ann Oncol; 2011 Feb; 22(2):268-79. PubMed ID: 20643861 [TBL] [Abstract][Full Text] [Related]
32. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. Bapat A; Glass LS; Luo M; Fishel ML; Long EC; Georgiadis MM; Kelley MR J Pharmacol Exp Ther; 2010 Sep; 334(3):988-98. PubMed ID: 20504914 [TBL] [Abstract][Full Text] [Related]
33. Detection of damaged DNA bases by DNA glycosylase enzymes. Friedman JI; Stivers JT Biochemistry; 2010 Jun; 49(24):4957-67. PubMed ID: 20469926 [TBL] [Abstract][Full Text] [Related]
34. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. Ferraris DV J Med Chem; 2010 Jun; 53(12):4561-84. PubMed ID: 20364863 [No Abstract] [Full Text] [Related]
35. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Abbotts R; Madhusudan S Cancer Treat Rev; 2010 Aug; 36(5):425-35. PubMed ID: 20056333 [TBL] [Abstract][Full Text] [Related]
37. The DNA-damage response in human biology and disease. Jackson SP; Bartek J Nature; 2009 Oct; 461(7267):1071-8. PubMed ID: 19847258 [TBL] [Abstract][Full Text] [Related]
38. Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. Zhu Y; Hu J; Hu Y; Liu W Cancer Treat Rev; 2009 Nov; 35(7):590-6. PubMed ID: 19635647 [TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. Simeonov A; Kulkarni A; Dorjsuren D; Jadhav A; Shen M; McNeill DR; Austin CP; Wilson DM PLoS One; 2009 Jun; 4(6):e5740. PubMed ID: 19484131 [TBL] [Abstract][Full Text] [Related]